Swiss contract manufacturer (CDMO) that makes peptide-based drug ingredients, including for GLP-1 obesity/diabetes drugs.
Swiss contract manufacturer (CDMO) that makes peptide-based drug ingredients, including for GLP-1 obesity/diabetes drugs.
Is paid for development work and for manufacturing batches of peptide ingredients under supply agreements, with a few big customers accounting for much of the volume, so one customer's order shift can sway a year. Its sites in Europe and the US supply both clinical and commercial drugs.
In one line: A peptide-manufacturing CDMO like a smaller Bachem Holding.
Moat: narrow (process know-how, regulatory licence, scale). Specialized peptide synthesis capacity and regulatory-approved manufacturing are scarce amid surging GLP-1 drug demand.
Headquarters: Zug, Switzerland · Founded: 1996 · Employees: 1,469
Size PolyPeptide (PPGN.SW) is a Switzerland Health Care company (Biotechnology) with a market value of $1.61B, the 103rd largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 41.05 on 18 Nov 2026.
Performance Over six months the shares gained 7.3%, against -12.8% for the median peer and +9.3% for the Switzerland market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue grew 22.1% over the last twelve months (peer median +33.8%); the operating margin is 7.0% (peer median -6.3%).
Valuation It trades at 52.1× forward earnings against a peer median of 20.4× (2nd most expensive of 9).
Capital Return on invested capital runs 0.3 points below its cost of capital (6.3% WACC).
Next results Next results expected around 9 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 424M | CHF 365M | CHF 321M | CHF 311M | CHF 282M |
| Revenue growth | — | +14% | +3% | +10% | — |
| Gross profit | CHF 95.9M | CHF 59.9M | CHF 34.4M | CHF 3.12M | CHF 50.9M |
| EBITDA | CHF 73.1M | CHF 41.4M | CHF 22.3M | -CHF 10.2M | CHF 36.3M |
| Net income | CHF 13.3M | -CHF 19.8M | -CHF 18.6M | -CHF 50.0M | CHF 7.80M |
| Free cash flow | -CHF 46.1M | -CHF 28.3M | CHF 3.48M | -CHF 15.9M | -CHF 69.9M |
| Capital expenditure | CHF 96.0M | CHF 102M | CHF 82.8M | CHF 55.1M | CHF 79.1M |
| Total debt | n/a | CHF 121M | CHF 88.3M | CHF 106M | CHF 21.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| PolyPeptide PPGN.SW | $1.61B | +7% | +22% | 7% | 52.1× | n/a |
| Bachem BANB.SW | $7.06B | 0% | +5% | 19% | 32.4× | n/a |
| Lonza LONN.SW | $53.9B | +36% | -11% | 25% | 36.1× | 15.6% |
| Wuxi Apptec 2359.HK | $64.1B | +51% | +38% | 44% | 19.5× | 8.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PPGN.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.8% | -9.9% | 8th highest of 21 |
| 6-month return | +7.3% | -12.8% | 4th highest of 20 |
| Distance from 52-week high | -18.1% | -45.0% | highest of 21 |
| Revenue growth (TTM) | +22.1% | +33.8% | 8th lowest of 19 |
| Operating margin | 7.0% | -6.3% | 9th highest of 19 |
| Forward P/E | 52.1× | 20.4× | 2nd most expensive of 9 |
| ROIC minus cost of capital | -0.3 pp | -10.8 pp | 5th highest of 15 |
| EV / EBITDA | 19.5× | 8.5× | 3rd most expensive of 6 |
| Net debt / EBITDA | 1.0× | -1.1× | 3rd most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| PolyPeptide PPGN.SW | Switzerland | $1.61B | +7% | +22% | 7% | 52.1× | n/a | n/a |
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.62B | +28% | +8% | -1,463% | n/a | n/a | n/a |
| Hitgen 688222.SS | China | $1.62B | -3% | +42% | 27% | 73.2× | 33.2% | +16.8% |
| Alvotech ALVO | United States | $1.62B | +38% | -14% | 12% | 22.6× | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.62B | -13% | +26% | 15% | 7.5× | -7.6% | +33.5% |
| Zhejiang Hengtong 600226.SS | China | $1.64B | -31% | +71% | 0% | 27.6× | n/a | n/a |
| Vir Biotechnology VIR | United States | $1.57B | +3% | +1,696% | -70% | n/a | n/a | n/a |
| Nurix Therapeutics NRIX | United States | $1.54B | -14% | +739% | 41% | n/a | n/a | n/a |
| Precigen PGEN | United States | $1.53B | 0% | +2,388% | 21% | 7.3× | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.53B | -41% | n/a | n/a | n/a | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.69B | -30% | +17% | 38% | 18.1× | -12.1% | +15.0% |
| Korsana Biosciences KRSA | United States | $1.52B | +54% | -64% | -5,277% | n/a | n/a | n/a |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.51B | -37% | +12% | 8% | n/a | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.50B | n/a | n/a | n/a | n/a | n/a | n/a |
| Peptron 087010.KS | South Korea | $1.49B | -68% | -13% | -488% | n/a | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.49B | -17% | +556% | -43% | n/a | n/a | n/a |
| Stoke Therapeutics STOK | United States | $1.75B | -12% | -86% | -913% | n/a | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.47B | -32% | +25% | 33% | 46.4× | n/a | n/a |
| Recursion Pharmaceuticals RXRX | United States | $1.76B | -5% | +56% | -725% | n/a | n/a | n/a |
| UroGen Pharma URGN | United States | $1.46B | -1% | +159% | -12% | 16.7× | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.46B | -51% | +90% | -297% | n/a | n/a | n/a |